Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Pfizer
M.D. Anderson Cancer Center
Erasca, Inc.
Pfizer
Actym Therapeutics, Inc.
Ikena Oncology
Eli Lilly and Company
Jonsson Comprehensive Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
Columbia University
Theratechnologies
Sotio Biotech Inc.
ABM Therapeutics Corporation
MacroGenics
Fore Biotherapeutics
Celgene
SWOG Cancer Research Network
Memorial Sloan Kettering Cancer Center
Valerio Therapeutics
Valerio Therapeutics
University of Chicago
Calando Pharmaceuticals
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey